142 assets in Cutaneous Melanoma

Therapeutic assets addressing Cutaneous Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dacarbazine Cutaneous Melanoma	Linnaeus Therapeutics, Inc.	P3	BBB (72)
TIL Cutaneous Melanoma	City of Hope Medical Center	P2	BBB (72)
Nivestim Cutaneous Melanoma	Vastra Gotaland Region	P3	BB (71)
Cediranib Cutaneous Melanoma	Jonsson Comprehensive Cancer Center	P3	BB (70)
Ipilimumab Cutaneous Melanoma	Amsterdam UMC, location VUmc	P3	BB (69)
Binimetinib Cutaneous Melanoma	Leiden University Medical Center	P3	BB (68)
Nivolumab Cutaneous Melanoma	Fred Hutchinson Cancer Center	P3	BB (68)
Sargramostim Cutaneous Melanoma	Mayo Clinic	P3	BB (68)
Cyclophosphamide Cutaneous Melanoma	East Metropolitan Health Service, Australia	P3	BB (66)
Dabrafenib Cutaneous Melanoma	Immuneering Corporation	P3	BB (66)
Lifileucel Cutaneous Melanoma	Vastra Gotaland Region	P3	BB (66)
Relatlimab Cutaneous Melanoma	University Health Network, Toronto	P3	BB (66)
Rph-075 Cutaneous Melanoma	R-Pharm	P3	BB (66)
Sorafenib Cutaneous Melanoma	National Cancer Institute (NCI)	P3	BB (66)
Atezolizumab Cutaneous Melanoma	EuroCityClinic LLC	P2	BB (65)
Carboplatin Cutaneous Melanoma	Immatics US, Inc.	P3	BB (65)
Pembrolizumab Cutaneous Melanoma	Melanoma Institute Australia	P3	BB (65)
Fludarabine Cutaneous Melanoma	East Metropolitan Health Service, Australia	P3	BB (64)
Interferon Alfa-2B Cutaneous Melanoma	National Cancer Institute (NCI)	P3	BB (64)
Melphalan Cutaneous Melanoma	Vastra Gotaland Region	P3	BB (64)
Selumetinib Cutaneous Melanoma	National Cancer Institute (NCI)	P2	BB (64)
Ziv-Aflibercept Cutaneous Melanoma	National Cancer Institute (NCI)	P2	B (63)
ima203 Cutaneous Melanoma	Immatics US, Inc.	P3	B (62)
Trametinib Cutaneous Melanoma	M.D. Anderson Cancer Center	P2	B (62)
Encorafenib Cutaneous Melanoma	University of Utah	P2	B (61)
Hydroxychloroquine Cutaneous Melanoma	ECOG-ACRIN Cancer Research Group	P2	B (61)
Montanide Isa 51 Cutaneous Melanoma	Dana-Farber Cancer Institute	P3	B (61)
Ibrutinib Cutaneous Melanoma	Mayo Clinic	P2	B (60)
Infliximab Cutaneous Melanoma	Therakos LLC	P2	B (59)
Riluzole Cutaneous Melanoma	National Cancer Institute (NCI)	P2	B (59)
Cabozantinib Cutaneous Melanoma	National Cancer Institute (NCI)	P2	B (58)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Cutaneous Melanoma	University of Louisville	P3	B (58)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Cutaneous Melanoma	University of California, Irvine	P2	B (58)
Lenvatinib Cutaneous Melanoma	Shanghai Zhongshan Hospital	P2	B (58)
Olaparib Cutaneous Melanoma	Dana-Farber Cancer Institute	P2	B (58)
Tocilizumab Cutaneous Melanoma	M.D. Anderson Cancer Center	P2	B (58)
Bcd-201 Cutaneous Melanoma	Biocad	P3	B (57)
Bcd-217 Cutaneous Melanoma	Biocad	P3	B (57)
Bcd-263 Cutaneous Melanoma	Biocad	P3	B (57)
Ngfr-Transduced Autologous T Lymphocytes Cutaneous Melanoma	M.D. Anderson Cancer Center	P1/2	B (57)
Prolgolimab Cutaneous Melanoma	Biocad	P3	B (57)
Technetium, Tc-99M Cutaneous Melanoma	Vastra Gotaland Region	P3	B (57)
Cobimetinib Cutaneous Melanoma	Mayo Clinic	P2	B (56)
lns8801 Cutaneous Melanoma	Linnaeus Therapeutics, Inc.	P2/3	CCC (55)
Prednisone Cutaneous Melanoma	National Cancer Institute (NCI)	P1/2	CCC (55)
Sirolimus Cutaneous Melanoma	National Cancer Institute (NCI)	P1/2	CCC (55)
Vedolizumab Cutaneous Melanoma	Therakos LLC	P2	CCC (55)
[203pb]vmt01 Cutaneous Melanoma	Perspective Therapeutics	P1/2	CCC (53)
Acasunlimab Cutaneous Melanoma	Genmab	P2	CCC (53)
Adriamycin Cutaneous Melanoma	GI Innovation, Inc.	P1/2	CCC (53)

Showing 1 to 50 of 142 assets

PreviousPage 1 of 3Next